NZ549898A - Optimized expression of HPV 52 L1 in yeast - Google Patents

Optimized expression of HPV 52 L1 in yeast

Info

Publication number: NZ549898A
Authority: NZ; New Zealand
Prior art keywords: hpv; protein; yeast; sequence; vlps
Prior art date: 2004-03-24

Application number

NZ549898A

Other languages

English (en)

Inventor

Janine T Bryan

Michelle K Brownlow

Loren D Schultz

Kathrin U Jansen

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-24

Filing date

2005-03-18

Publication date

2009-06-26

2005-03-18 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2009-06-26 Publication of NZ549898A publication Critical patent/NZ549898A/en

Links

240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 64
239000002773 nucleotide Substances 0.000 claims abstract description 37
125000003729 nucleotide group Chemical group 0.000 claims abstract description 37
210000005253 yeast cell Anatomy 0.000 claims abstract description 28
239000002245 particle Substances 0.000 claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 8
108090000623 proteins and genes Proteins 0.000 claims description 119
102000004169 proteins and genes Human genes 0.000 claims description 87
235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 60
210000004027 cell Anatomy 0.000 claims description 48
238000000034 method Methods 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 24
102000039446 nucleic acids Human genes 0.000 claims description 22
108020004707 nucleic acids Proteins 0.000 claims description 22
239000013598 vector Substances 0.000 claims description 21
208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 11
241001631646 Papillomaviridae Species 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 8
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
230000001939 inductive effect Effects 0.000 claims description 5
241000701828 Human papillomavirus type 11 Species 0.000 claims description 4
241000235058 Komagataella pastoris Species 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
241000320412 Ogataea angusta Species 0.000 claims description 4
230000028993 immune response Effects 0.000 claims description 4
235000014663 Kluyveromyces fragilis Nutrition 0.000 claims description 3
241001138401 Kluyveromyces lactis Species 0.000 claims description 3
241000235650 Kluyveromyces marxianus Species 0.000 claims description 3
241000235347 Schizosaccharomyces pombe Species 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
230000001131 transforming effect Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims 2
241000235070 Saccharomyces Species 0.000 claims 1
210000005260 human cell Anatomy 0.000 claims 1
241000701806 Human papillomavirus Species 0.000 abstract description 230
229960005486 vaccine Drugs 0.000 abstract description 24
108091033319 polynucleotide Proteins 0.000 abstract description 13
102000040430 polynucleotide Human genes 0.000 abstract description 13
239000002157 polynucleotide Substances 0.000 abstract description 13
230000005030 transcription termination Effects 0.000 abstract description 11
230000003472 neutralizing effect Effects 0.000 abstract description 5
238000011282 treatment Methods 0.000 abstract description 5
230000024932 T cell mediated immunity Effects 0.000 abstract description 2
108700042300 human papillomavirus type 52 L1 Proteins 0.000 abstract 2
235000018102 proteins Nutrition 0.000 description 74
108020004705 Codon Proteins 0.000 description 36
108020004414 DNA Proteins 0.000 description 31
101150034230 LI gene Proteins 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
239000000203 mixture Substances 0.000 description 14
150000001413 amino acids Chemical group 0.000 description 13
239000013612 plasmid Substances 0.000 description 11
239000012634 fragment Substances 0.000 description 10
239000000499 gel Substances 0.000 description 10
238000003752 polymerase chain reaction Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
238000011161 development Methods 0.000 description 8
239000000600 sorbitol Substances 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
238000000636 Northern blotting Methods 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000012552 review Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 6
239000000284 extract Substances 0.000 description 6
230000001105 regulatory effect Effects 0.000 description 6
230000035897 transcription Effects 0.000 description 6
238000013518 transcription Methods 0.000 description 6
108010058643 Fungal Proteins Proteins 0.000 description 5
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
108700005078 Synthetic Genes Proteins 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
238000012258 culturing Methods 0.000 description 5
229930182830 galactose Natural products 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
231100000590 oncogenic Toxicity 0.000 description 5
230000002246 oncogenic effect Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
238000010186 staining Methods 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
206010008342 Cervix carcinoma Diseases 0.000 description 4
108700010070 Codon Usage Proteins 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000008272 agar Substances 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
201000010881 cervical cancer Diseases 0.000 description 4
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
229960005542 ethidium bromide Drugs 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229960002566 papillomavirus vaccine Drugs 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
238000004627 transmission electron microscopy Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000001262 western blot Methods 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
108090000565 Capsid Proteins Proteins 0.000 description 3
102100023321 Ceruloplasmin Human genes 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
238000001712 DNA sequencing Methods 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241000341655 Human papillomavirus type 16 Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
208000000260 Warts Diseases 0.000 description 3
238000000246 agarose gel electrophoresis Methods 0.000 description 3
238000000137 annealing Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
208000019065 cervical carcinoma Diseases 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229930027917 kanamycin Natural products 0.000 description 3
229960000318 kanamycin Drugs 0.000 description 3
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
229930182823 kanamycin A Natural products 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
201000010153 skin papilloma Diseases 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 2
101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 2
101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 2
101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 2
101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
101150094690 GAL1 gene Proteins 0.000 description 2
102100028501 Galanin peptides Human genes 0.000 description 2
101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101710121996 Hexon protein p72 Proteins 0.000 description 2
101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
101100121078 Homo sapiens GAL gene Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000007993 MOPS buffer Substances 0.000 description 2
101710125418 Major capsid protein Proteins 0.000 description 2
101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 2
101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 2
101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 2
101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 2
101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 2
101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 2
101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 2
101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 2
101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 2
101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229940037003 alum Drugs 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
235000020030 perry Nutrition 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000002028 premature Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000012798 spherical particle Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229940021747 therapeutic vaccine Drugs 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
COAABSMONFNYQH-TTWCUHKNSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(oxiran-2-ylmethylsulfanyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1SCC1OC1 COAABSMONFNYQH-TTWCUHKNSA-N 0.000 description 1
DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
101100480861 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) tdh gene Proteins 0.000 description 1
101100447466 Candida albicans (strain WO-1) TDH1 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
101150038242 GAL10 gene Proteins 0.000 description 1
102100024637 Galectin-10 Human genes 0.000 description 1
102100039555 Galectin-7 Human genes 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 1
101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710157639 Minor capsid protein Proteins 0.000 description 1
241001467460 Myxogastria Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
101710136297 Protein VP2 Proteins 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
101150039863 Rich gene Proteins 0.000 description 1
101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
210000002255 anal canal Anatomy 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
239000011324 bead Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000013578 denaturing buffer Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
108010087005 glusulase Proteins 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
208000024312 invasive carcinoma Diseases 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
229940032313 prophylactic HPV vaccine Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
210000001533 respiratory mucosa Anatomy 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
101150088047 tdh3 gene Proteins 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NZ549898A 2004-03-24 2005-03-18 Optimized expression of HPV 52 L1 in yeast NZ549898A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55592604P	2004-03-24	2004-03-24
PCT/US2005/009199 WO2005097821A1 (en)	2004-03-24	2005-03-18	Optimized expression of hpv 52 l1 in yeast

Publications (1)

Publication Number	Publication Date
NZ549898A true NZ549898A (en)	2009-06-26

Family

ID=34964085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ549898A NZ549898A (en)	2004-03-24	2005-03-18	Optimized expression of HPV 52 L1 in yeast

Country Status (31)

Country	Link
US (2)	US7700103B2 (sl)
EP (1)	EP1730175B1 (sl)
JP (1)	JP4833962B2 (sl)
KR (1)	KR101203403B1 (sl)
CN (1)	CN1934131B (sl)
AR (1)	AR048191A1 (sl)
AT (1)	ATE466022T1 (sl)
AU (1)	AU2005230907C1 (sl)
BE (1)	BE2015C066I2 (sl)
BR (1)	BRPI0509079B8 (sl)
CA (1)	CA2560487C (sl)
CY (2)	CY1110349T1 (sl)
DE (1)	DE602005020913D1 (sl)
DK (1)	DK1730175T3 (sl)
ES (1)	ES2343255T3 (sl)
FR (1)	FR15C0085I2 (sl)
HU (1)	HUS1500062I1 (sl)
IL (1)	IL178140A (sl)
LT (2)	LTC1730175I2 (sl)
LU (1)	LU92903I2 (sl)
MY (1)	MY148656A (sl)
NL (1)	NL300777I2 (sl)
NO (3)	NO338055B1 (sl)
NZ (1)	NZ549898A (sl)
PL (1)	PL1730175T3 (sl)
PT (1)	PT1730175E (sl)
RU (1)	RU2373219C2 (sl)
SI (1)	SI1730175T1 (sl)
TW (1)	TWI349036B (sl)
WO (1)	WO2005097821A1 (sl)
ZA (1)	ZA200607575B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7858098B2 (en) *	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
CN1869215B (zh) *	2006-05-19	2012-07-04	长春百克生物科技股份公司	一种制备人乳头瘤病毒的病毒样颗粒的方法
JP2010520874A (ja)	2007-03-09	2010-06-17	メルク・シャープ・エンド・ドーム・コーポレイション	パピローマウイルスワクチン組成物
EP2479186B1 (en) *	2007-11-23	2015-08-12	Shanghai Zerun Biotechnology Co., Ltd.	Genes encoding major capsid protein L1 of human papilloma viruses
CN101440371B (zh) *	2007-11-23	2012-09-05	上海泽润生物科技有限公司	一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
EP3705133B1 (en) *	2010-05-14	2024-06-26	Baxalta Incorporated	Ospa chimeras and use thereof in vaccines
AU2011258501B2 (en)	2010-05-25	2016-07-07	Qiagen Gaithersburg, Inc.	Fast results hybrid capture assay and associated strategically-truncated probes
CN102268076B (zh) *	2010-07-02	2017-04-26	厦门大学	截短的人乳头瘤病毒52型l1蛋白
US8361720B2 (en)	2010-11-15	2013-01-29	Exact Sciences Corporation	Real time cleavage assay
EP2646559A2 (en)	2010-12-03	2013-10-09	MS Technologies, LLC	Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CN102154325B (zh) *	2011-01-01	2013-08-21	上海生物制品研究所有限责任公司	针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445357C1 (ru) *	2011-02-15	2012-03-20	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) *	2011-02-15	2012-03-20	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
CN110484554B (zh) *	2013-04-26	2024-04-16	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) *	2013-05-17	2019-12-20	北京安百胜生物科技有限公司	用汉逊酵母表达系统产生hpv31 l1蛋白的方法
EP3057612B1 (en)	2013-10-16	2020-05-06	Merck Sharp & Dohme Corp.	Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) *	2015-04-27	2015-09-02	段青姣	编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) *	2015-08-12	2021-11-16	北京康乐卫士生物技术股份有限公司	52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) *	2017-11-07	2023-08-18	上海泽润生物科技有限公司	重组人乳头瘤病毒52亚型蛋白表达
JP2023516904A (ja)	2020-02-14	2023-04-21	メルク・シャープ・アンド・ドーム・エルエルシー	Ｈｐｖワクチン
CN114539365B (zh) *	2020-11-26	2023-12-01	中国医学科学院基础医学研究所	一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) *	2021-03-23	2023-06-13	重庆博唯佰泰生物制药有限公司	一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) *	2021-06-07	2023-03-31	郑州大学	编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
EP4380615A1 (en)	2021-08-06	2024-06-12	Merck Sharp & Dohme LLC	Hpv vaccine
JP2024532127A (ja)	2021-08-19	2024-09-05	メルク・シャープ・アンド・ドーム・エルエルシー	熱安定性脂質ナノ粒子およびその使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1339729C (en) *	1988-10-26	1998-03-17	Wayne D. Lancaster	Human papillomavirus type 52 dna sequences and methods for employing thesame
US5821087A (en)	1995-03-30	1998-10-13	Merck & Co., Inc.	Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en)	1995-03-30	1996-07-23	Merck & Co Inc	Synthetic DNA encoding human papillomavirus type 11 L1 protein
DK0969862T3 (da)	1997-02-07	2007-02-12	Merck & Co Inc	Syntetisk HIV gag-gener
JP4434479B2 (ja)	1997-07-09	2010-03-17	ザ・ユニバーシティ・オブ・クイーンズランド	標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
ES2262333T3 (es) *	1998-08-14	2006-11-16	MERCK & CO., INC.	Procedimiento para purificar particulas similares a virus de papilomavirus humano.
EP1105157B1 (en)	1998-08-14	2006-11-02	Merck & Co., Inc.	Protein delivery system using human papillomavirus virus-like particles
SE514982C2 (sv) *	1999-09-30	2001-05-28	Active Biotech Ab	Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE60016765T2 (de) *	1999-08-25	2005-11-24	Merck & Co., Inc.	Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en)	1999-10-15	2002-08-20	Merck & Co., Inc.	Process for making human papillomavirus virus-like particles with improved properties
DK1301614T3 (da)	2000-07-21	2007-04-02	Glaxo Group Ltd	Codon-optimerede papillomavirus-sekvenser
US20030226155A1 (en) *	2001-08-30	2003-12-04	Biorexis Pharmaceutical Corporation	Modified transferrin-antibody fusion proteins
NZ542246A (en)	2003-03-24	2007-12-21	Merck & Co Inc	Optimized expression of HPV 31 L1 yeast
MY140664A (en)	2003-09-29	2010-01-15	Merck Sharp & Dohme	Optimized expression of hpv 45 l1 in yeast
MY139500A (en) *	2003-11-12	2009-10-30	Merck Sharp & Dohme	Optimized expression of hpv 58 l1 in yeast

2005
- 2005-03-18 NZ NZ549898A patent/NZ549898A/en unknown
- 2005-03-18 CA CA2560487A patent/CA2560487C/en active Active
- 2005-03-18 RU RU2006137363/13A patent/RU2373219C2/ru active
- 2005-03-18 SI SI200531052T patent/SI1730175T1/sl unknown
- 2005-03-18 EP EP05725933A patent/EP1730175B1/en active Active
- 2005-03-18 DK DK05725933.5T patent/DK1730175T3/da active
- 2005-03-18 DE DE602005020913T patent/DE602005020913D1/de active Active
- 2005-03-18 AU AU2005230907A patent/AU2005230907C1/en active Active
- 2005-03-18 AT AT05725933T patent/ATE466022T1/de active
- 2005-03-18 PL PL05725933T patent/PL1730175T3/pl unknown
- 2005-03-18 US US10/594,064 patent/US7700103B2/en active Active
- 2005-03-18 ES ES05725933T patent/ES2343255T3/es active Active
- 2005-03-18 BR BRPI0509079A patent/BRPI0509079B8/pt active IP Right Grant
- 2005-03-18 CN CN2005800095956A patent/CN1934131B/zh active Active
- 2005-03-18 WO PCT/US2005/009199 patent/WO2005097821A1/en active Application Filing
- 2005-03-18 PT PT05725933T patent/PT1730175E/pt unknown
- 2005-03-18 KR KR1020067019673A patent/KR101203403B1/ko active IP Right Grant
- 2005-03-18 TW TW094108431A patent/TWI349036B/zh active
- 2005-03-18 MY MYPI20051180A patent/MY148656A/en unknown
- 2005-03-18 JP JP2007505032A patent/JP4833962B2/ja active Active
- 2005-03-23 AR ARP050101174A patent/AR048191A1/es active IP Right Grant
2006
- 2006-09-11 ZA ZA200607575A patent/ZA200607575B/xx unknown
- 2006-09-17 IL IL178140A patent/IL178140A/en active IP Right Grant
- 2006-10-23 NO NO20064815A patent/NO338055B1/no active Protection Beyond IP Right Term
2009
- 2009-10-14 US US12/578,995 patent/US7744892B2/en active Active
2010
- 2010-07-26 CY CY20101100698T patent/CY1110349T1/el unknown
2015
- 2015-11-30 NL NL300777C patent/NL300777I2/nl unknown
- 2015-12-02 HU HUS1500062C patent/HUS1500062I1/hu unknown
- 2015-12-04 FR FR15C0085C patent/FR15C0085I2/fr active Active
- 2015-12-07 CY CY2015052C patent/CY2015052I1/el unknown
- 2015-12-08 LU LU92903C patent/LU92903I2/xx unknown
- 2015-12-08 LT LTPA2015050C patent/LTC1730175I2/lt unknown
- 2015-12-08 LT LTPA2015050D patent/LTPA2015050I1/lt unknown
- 2015-12-09 BE BE2015C066C patent/BE2015C066I2/nl unknown
2017
- 2017-01-20 NO NO2017005C patent/NO2017005I1/no unknown
2022
- 2022-11-30 NO NO2022050C patent/NO2022050I1/no unknown

Also Published As

Publication number	Publication date
MY148656A (en)	2013-05-15
TWI349036B (en)	2011-09-21
NO338055B1 (no)	2016-07-25
HUS1500062I1 (hu)	2017-07-28
US20100035818A1 (en)	2010-02-11
PL1730175T3 (pl)	2010-09-30
SI1730175T1 (sl)	2010-08-31
BRPI0509079B1 (pt)	2020-05-19
NL300777I1 (sl)	2015-12-29
TW200602490A (en)	2006-01-16
AU2005230907B2 (en)	2011-05-19
LTPA2015050I1 (lt)	2016-01-11
KR20060134120A (ko)	2006-12-27
CA2560487A1 (en)	2005-10-20
US7744892B2 (en)	2010-06-29
NO20064815L (no)	2006-10-23
JP4833962B2 (ja)	2011-12-07
AR048191A1 (es)	2006-04-05
FR15C0085I1 (sl)	2016-08-01
IL178140A (en)	2010-11-30
EP1730175A1 (en)	2006-12-13
RU2373219C2 (ru)	2009-11-20
DK1730175T3 (da)	2010-08-23
ZA200607575B (en)	2008-08-27
IL178140A0 (en)	2006-12-31
FR15C0085I2 (fr)	2016-11-25
BRPI0509079A (pt)	2007-08-21
NO2017005I1 (no)	2017-01-20
CY2015052I2 (el)	2016-06-22
AU2005230907A1 (en)	2005-10-20
BE2015C066I2 (sl)	2024-08-08
LTC1730175I2 (lt)	2017-05-10
ES2343255T3 (es)	2010-07-27
LU92903I2 (fr)	2016-03-08
PT1730175E (pt)	2010-06-25
ATE466022T1 (de)	2010-05-15
US7700103B2 (en)	2010-04-20
WO2005097821A1 (en)	2005-10-20
BRPI0509079B8 (pt)	2021-07-06
US20080226660A1 (en)	2008-09-18
EP1730175B1 (en)	2010-04-28
NL300777I2 (sl)	2015-12-29
CY1110349T1 (el)	2015-04-29
DE602005020913D1 (de)	2010-06-10
NO2022050I1 (no)	2022-11-30
AU2005230907C1 (en)	2016-07-28
JP2007530040A (ja)	2007-11-01
CY2015052I1 (el)	2016-06-22
CA2560487C (en)	2013-01-29
RU2006137363A (ru)	2008-04-27
CN1934131B (zh)	2010-12-29
CN1934131A (zh)	2007-03-21
KR101203403B1 (ko)	2012-11-21

Publication	Publication Date	Title
US7744892B2 (en)	2010-06-29	Optimized expression of HPV 52 L1 in yeast
AU2004290032B2 (en)	2009-02-05	Optimized expression of HPV 58 L1 in yeast
US7482015B2 (en)	2009-01-27	Optimized expression of HPV 45 L1 in yeast
EP1608767B1 (en)	2012-02-22	Optimized expression of hpv 31 l1 in yeast
MXPA06010983A (en)	2007-04-20	Optimized expression of hpv 52 l1 in yeast
MXPA06005306A (en)	2006-10-17	Optimized expression of hpv 58 l1 in yeast

Legal Events

Date	Code	Title	Description
2009-04-30	RENW	Renewal (renewal fees accepted)
2009-10-30	PSEA	Patent sealed
2012-01-27	RENW	Renewal (renewal fees accepted)
2012-08-31	ASS	Change of ownership	Owner name: SCHERING CORPORATION, US Free format text: OLD OWNER(S): MERCK SHARP AND DOHME CORP.
2014-12-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2016 BY THOMSON REUTERS Effective date: 20141221
2016-02-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2017 BY THOMSON REUTERS Effective date: 20160217
2017-02-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2018 BY THOMSON REUTERS Effective date: 20170221
2018-02-23	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2019 BY THOMSON REUTERS Effective date: 20180217
2019-02-22	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2020 BY THOMSON REUTERS Effective date: 20190216
2020-02-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2021 BY THOMSON REUTERS Effective date: 20200205
2021-02-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2022 BY THOMSON REUTERS Effective date: 20210206
2022-03-25	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2023 BY THOMSON REUTERS Effective date: 20220302
2022-09-30	ASS	Change of ownership	Owner name: MERCK SHARP + DOHME LLC, US Effective date: 20220922
2023-02-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2024 BY THOMSON REUTERS Effective date: 20230201
2024-02-23	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2025 BY THOMSON REUTERS Effective date: 20240201